中国药物评价2025，Vol.42Issue(1)：6-10,5.
白芍总苷胶囊治疗类风湿关节炎的临床综合评价
Comprehensive Clinical Evaluation of Total Glucosides of White Paeony Capsules in the Treatment of Rheumatoid Arthritis
黄正明 1栗占国 2赵岩 3伍沪生 4刘燕鹰 5杨新波 1洪舟6
作者信息
- 1. 中国医药教育协会,北京 100071
- 2. 北京大学人民医院,北京 100044
- 3. 北京协和医院,北京 100730
- 4. 北京积水潭医院,北京 102208
- 5. 北京友谊医院,北京 100050
- 6. 宁波天然植物提取协会,浙江宁波 315101
- 折叠
摘要
Abstract
Objective:To evaluate the clinical comprehensive value of Total Glucosides of White Paeony Capsules in the treatment of rheumatoid arthritis,thus providing more optimal guidance for clinical drug use.Methods:According to the"Notice on Launching the Work of Drug Use Monitoring and Clinical Comprehensive Evaluation",the safety,effectiveness,economy,innovation,suitability,and accessibility of Total Glucosides of White Paeony Capsules were evaluated clinically comprehensively.Results:The safety evaluation showed that the adverse reactions of Total Glucosides of White Paeony Capsules were mild in clinical use,and the safety was good.The pharmacodynamic study showed that the efficacy of Total Glucosides of White Paeony Capsules in the treatment of rheumatoid arthritis was significant,and the clinical effective rate was superior to that of hydroxychloroquine.The economic study showed that Total Glucosides of White Paeony Capsules was cheaper than hydroxychloroquine,and could be considered as an advantageous scheme.There was sufficient evidence of intellectual property innovation and clinical innovation in Total Glucosides of White Paeony Capsules,and it was a drug cov-ered by the national basic medical insurance system,with obvious advantages in clinical accessibility and availability.Conclusion:Total Glucosides of White Paeony Capsules has shown good clinical application value in the treatment of rheumatoid arthritis.关键词
白芍总苷胶囊/类风湿关节炎/安全性/有效性/临床综合评价Key words
Total glucosides of white paeony capsules/Rheumatoid arthritis/Security/Effectiveness/Clinical comprehensive evaluation分类
药学引用本文复制引用
黄正明,栗占国,赵岩,伍沪生,刘燕鹰,杨新波,洪舟..白芍总苷胶囊治疗类风湿关节炎的临床综合评价[J].中国药物评价,2025,42(1):6-10,5.
